Background:
Adults with neurological or cerebrovascular (NeCVD) disease have an elevated risk of influenza-related complications. Whether HD-IIV provides greater relative benefit over SD-IIV in this population is uncertain.
Objective:
To evaluate the relative vaccine effectiveness (rVE) of high-dose inactivate...
M. Yafasov, N. Johansen, D. Modin et al.· Circulation· 0 citations
While impaired left atrial (LA) function has been linked to an increased risk of cardiovascular outcomes, recent investigations has focused on LA longitudinal strain. However, data are limited on which LA functional parameter provides the strongest prognostic information regarding the long-term risk of incident h...
A. Nielsen, K. Skaarup, R. Hauser et al.· European Heart Journal· 0 citations
The clinical relevance of left atrial (LA) dysfunction in acute heart failure (AHF) is unclear. Whether LA strain reflects disease mechanisms and predicts adverse outcomes in this heterogeneous population remains insufficiently investigated.
The aim was to examine the relationships between LA reservoir str...
M. Pedersen, F. Davidovski, C. Espersen et al.· European Heart Journal· 0 citations
AIM
This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo.
METHODS
COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine...
A. Langhoff, N. Johansen, K. Bartholdy et al.· European Journal of Preventi...· 0 citations
BACKGROUND
Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...
M. Lassen, S. Christensen, M. Yafasov et al.· NEJM Evidence· 1 citation
BACKGROUND
Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty...
C. Espersen, N. Johansen, D. Modin et al.· The Lancet Healthy Longevity· 0 citations
In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.
A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al.· The Lancet Healthy Longevity· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.